Cingulate Inc.CINGEarnings & Financial Report
Cingulate Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system disorders, including attention-deficit/hyperactivity disorder, anxiety and depression. It primarily operates in the U.S. market, focusing on advancing its proprietary precision drug delivery platform to improve patient outcomes across psychiatric and neurological care segments.
CING Q2 FY2025 Key Financial Metrics
Revenue
$-136.9K
Gross Profit
N/A
Operating Profit
$-4.6M
Net Profit
$-5.0M
Gross Margin
N/A
Operating Margin
3395.9%
Net Margin
3639.3%
YoY Growth
-3815.6%
EPS
$-1.09
Cingulate Inc. Q2 FY2025 Financial Summary
Cingulate Inc. reported revenue of $-136.9K (down 3815.6% YoY) for Q2 FY2025, with a net profit of $-5.0M (down 54.3% YoY) (3639.3% margin).
Key Financial Metrics
| Total Revenue | $-136.9K |
|---|---|
| Net Profit | $-5.0M |
| Gross Margin | N/A |
| Operating Margin | 3395.9% |
| Report Period | Q2 FY2025 |
Cingulate Inc. Quarterly Revenue & Net Profit History
Cingulate Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $-136.9K | -3815.6% | $-5.0M | 3639.3% |
| Q1 FY2025 | $-96.8K | -298.9% | $-3.9M | 3980.7% |
| Q2 FY2024 | $-3.5K | — | $-3.2M | 92375.9% |
| Q1 FY2024 | $-24.3K | — | $-3.0M | 12252.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|
| Revenue | $-24260 | $-3497 | $-96784 | $-136930 |
| YoY Growth | N/A | N/A | -298.9% | -3815.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|
| Assets | $5.5M | $5.1M | $12.5M | $13.5M |
| Liabilities | $2.3M | $2.0M | $6.5M | $8.0M |
| Equity | $3.2M | $3.1M | $5.9M | $5.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|
| Operating CF | $-8.7M | $-1.7M | $-4.6M | $-4.8M |